Sitagliptin (phosphate monohydrate)

Key facts

Invented name
Tesavel
Active substance
Sitagliptin (phosphate monohydrate)
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0129/2016
PIP number
Sitagliptin (phosphate monohydrate)
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Type 2 diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Merck Sharp and Dohme (Europe), Inc.
Belgium
E-mail: paul.robinson@merck.com
Tel. +44 1992452396
Fax +44 1992468175
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating